Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy Journal Article

Local Library Link: Find It @ Loyola

Authors: Choi, M; Kim, C. R.; Hung, A. Y.
Article Title: Salvage intensity-modulated radiation therapy for locally recurrent prostate cancer after cryotherapy
Abstract: BACKGROUND: To summarize our results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. MATERIALS AND METHODS: Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. Radiation was delivered to a minimum dose of 72 Gy (range, 72-81 Gy). Acute and late treatment-related gastrointestinal and genitourinary effects were scored according to Common Toxicity Criteria version 3.0. Prostate-specific antigen failure was defined by Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition. RESULTS: Nine patients were treated from 2008 to 2010. The median follow-up was 31 months (range, 15-40 months). The mean preradiotherapy prostate-specific antigen was 4.3 ng/mL (range, 1.07-15.6 ng/mL). The median elapsed time between cryotherapy and IMRT was 20.5 months (range, 8.5-56.5 months). Biochemical control was achieved in 7 patients. Two patients developed distant metastases shortly after completion of radiotherapy. No patients experienced grade 3 or higher toxicities. CONCLUSIONS: Our results suggest that high-dose IMRT after cryotherapy failure is well tolerated, without severe morbidity. The results also showed that IMRT can render a significant number of patients biochemically free of disease after initial cryotherapy. High-dose IMRT should be considered as a treatment option for these potentially salvageable cases.
Journal Title: Clinical genitourinary cancer
Volume: 11
Issue: 2
ISSN: 1938-0682; 1558-7673
Publisher: Elsevier Inc  
Journal Place: United States
Date Published: 2013
Start Page: 85
End Page: 88
Language: eng
DOI/URL:

10.1016/j.clgc.2012.09.003
Notes: CI: Copyright (c) 2013; JID: 101260955; EC 3.4.21.77 (Prostate-Specific Antigen); 2012/05/28 [received]; 2012/08/30 [revised]; 2012/09/13 [accepted]; 2012/10/05 [aheadofprint]; ppublish